期刊文献+

血清人附睾分泌蛋白4检测在卵巢癌诊断中的临床应用 被引量:9

Clinical Value of Serum Human Epididymial Protein 4 in The Diagnosis of Ovarian Cancer
原文传递
导出
摘要 [目的]探讨人附睾分泌蛋白4(human epididymial protein 4,HE4)在卵巢癌诊断中的价值。[方法]采用酶联免疫吸附试验和化学发光法检测48例卵巢癌患者、33例卵巢良性肿瘤患者以及38例健康体检者血清HE4以及糖类抗原125(CA125)的水平。[结果]血清HE4诊断卵巢癌的ROC曲线下面积为0.921(95%CI:0.887~0.955)。HE4 86.5pmol/L为阈值时诊断敏感度为66.7%,特异性为84.5%。而血清CA125诊断卵巢癌的ROC曲线下面积为0.902(95%CI:0.857~0.947)。CA125 48.2U/ml为阈值时诊断敏感度为62.5%,特异性为81.7%。HE4与CA125联合检测诊断卵巢癌的ROC曲线下面积为0.947(95%CI:0.914~0.980)。卵巢癌Ⅲ~Ⅳ期患者血清HE4水平明显高于Ⅰ~Ⅱ期患者(P〈0.001),有淋巴结转移患者血清HE4水平明显高于无淋巴结转移患者(P〈0.001)。[结论]HE4可作为卵巢癌诊断的血清学标志物,且与CA125联合检测可提高卵巢癌诊断效率。 [Purpose] To evaluate the diagnostic value of human epididymal protein 4(HE4) for ovarian cancer.[Methods] Forty-eight cases with ovarian cancer,33 cases with benign ovarian tumor and 38 cases of healthy control were enrolled.Serum HE4 and carbohydrate antigen 125(CA125) level were detected by enzyme-linked immunosorbent assay and chemiluminescence assay.[Results] The area of ROC curve of HE4 for ovarian cancer diagnosis was 0.921(95%CI: 0.887 ~0.955).The sensitivity was 66.7% and specificity was 84.5% while HE4 cut-off was 86.5pmol/L.The area of ROC curve of CA125 for ovarian cancer diagnosis was 0.902(95%CI: 0.857 ~0.947).The sensitivity was 62.57% and specificity was 81.7% while CA125 cut-off was 48.2 U/ml.The area of ROC curve of HE4 combined with CA125 for ovarian cancer diagnosis was 0.947(95%CI:0.914~0.980).Serum HE4 level in patients with stage Ⅲ~ Ⅳ or with lymph node metastasis was significantly higher than in stage Ⅰ~Ⅱ or without lymph node metastasis respectively(P0.05).[Conclusion] HE4 might be used as a serum marker in the diagnosis of ovarian cancer.It can improve the efficiency of diagnosis of ovarian cancer when combined with CA125.
作者 缪亚梅 金梅
出处 《中国肿瘤》 CAS 2013年第10期838-840,共3页 China Cancer
关键词 卵巢癌 人附睾分泌蛋白4 糖类抗原125 ovarian cancer human epididymal protein 4 carbohydrate antigen 125 tumor marker
  • 相关文献

参考文献2

二级参考文献30

  • 1Goonewardene TI, Hall MR, Rustin GJ. Management of asymptornatic patients on follow-up for ovarian cancer with rising CA-125 coneentra- tions[J]. Lancet Oncol, 2007,8 (9) : 813-821.
  • 2Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive a- nalysis of HE4 expression in normal and malignant human tis- sues[J]. ModPathol,2006,1(19):847 853.
  • 3Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma sub-types are different disease implications for biomarker studies [J]. Plos Med,2008,5(12) :232.
  • 4Bandiera E, Ragnoli M, Zanotti L. Clinical role of human epididy- mis protein 4 (HE4) in epithelial ovarian cancer[J]. Oncol, 2009,1(3) : 143.
  • 5Ailard J,Somers E,Theil R,et al. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer[J]. Cln On col,2008,26(15) :5535.
  • 6Anderson GL,McIntoshMW. Assessing lead time of selected o varian cancer biomarkers:a nested case-control study[J]. JNCI, 2010,102(1):438.
  • 7Langmcr Z,Nemeth M,Vlesko G,et al. HE4-a novel promising serum marker in the diagnosis of ovarian carci-noma[J]. Eur J Gynaecol Oncol,2011 ,32(6):605-610.
  • 8Moore RG,McMeekin DS,Brown AK,et al.A novel mul-tiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with apelvic mass[J].Gynecol Oncol,2009, 112(1):40-46.
  • 9Moore RG,Jabre-Raughley M,Brown AK,et al.Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in pa-tients with a pelvic mass[J].Am J Obstet Gynecol,2010,203 (3):228-236.
  • 10Fischerova D,Zikun M,Pinkavovu I,et al.The rational preoperative diagnosis of ovarian tumors-imaging tech-niques and tumor biomarkers[J]. Ceska Gynekol, 2012 , 77 (4):272-287.

共引文献31

同被引文献74

  • 1焦彦华,王秀艳,刘叶廷.血清CA125、CA72-4、CA199单项检测及联合检测对诊断卵巢癌的临床价值[J].现代养生,2013,0(24):72-72. 被引量:2
  • 2Oberaigner W,Minicozzi P,Bielska-Lasota M,et al.Survival for ovarian cancer in Europe:the across-country variation did not shrink in the past decade[J].Acta Oncol,2012,51(4):441-453.
  • 3Anderson GL,Mcintosh M,Wu L,et al.Assessing lead time of selected ovarian cancer biomarkers:a nestefd case-control study[J].J Natl Cancer Inst,2010,102(1):26-38.
  • 4Montagnana M,Danese E,Giudici S,et al.HE4 in ovarian cancer from discovery to clinical application[J].Adv Clin Chem,2011,55:1-20.
  • 5Cramer DW,Bast RC Jr,Berg CD,et al.Ovarian cancer biomarker performance in prostate,lung,colorectal,and ovarian cancer screening trial specimens[J].Cancer Prev Res(Phila),2011,4(3):365-374.
  • 6Kalogera E,Scholler N,Powless C,et al.Correlation of serum HE4with tumor size and myometrial invasion in endometrial cancer[J].Gynecol Oncol,2012,124(2):270-275.
  • 7Granato T,Midulla C,Longo F,et al.Role of HE4,CA72.4,and CA125 in monitoring ovarian cancer[J],Tumour Biol,2012,33(5):1335-1339.
  • 8Li F,Tie R,Chang K,et al. Does risk for ovarian malig- nancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer,a meta-anal- ysis[J]. BMC Cancer, 2012,12(2) . 258.
  • 9Yu S,Yang HJ,Xie SQ,et al. Diagnostic value of HE4 for ovarian cancer: a meta-analysis[J]. Clin Chem Lab Med, 2012,50(8) : 1439-1446.
  • 10Galgano MT, Hampton GM, Frierson HF. Comprehensive analysis of HE4 expression in normal and malignant hu- man tissues[J]. Mod Pathol,2006,19 (6) : 847-853.

引证文献9

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部